SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2016
Commission File Number: 001-37710
HUTCHISON CHINA MEDITECH LIMITED
(Translation of registrants name into English)
22/F, Hutchison House, 10 Harcourt Road, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
HUTCHISON CHINA MEDITECH LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Announcement relating to directors share dealing |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
HUTCHISON CHINA MEDITECH LIMITED | |
|
|
|
|
|
|
|
By: |
/s/ Johnny Cheng |
|
Name: |
Johnny Cheng |
|
Title: |
Chief Financial Officer |
Date: August 9, 2016
Exhibit 99.1
Directors Share Dealing
London: Tuesday, August 9, 2016: Hutchison China MediTech Limited (Chi-Med) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US$1.00 each in Chi-Med (the Ordinary Shares) at a price of GBP19.00 and GBP18.99 per share respectively on August 4, 2016.
Following the above transaction, the combined holding of Mr Nash and his spouse is 39,596 Ordinary Shares, representing approximately 0.065% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 |
Details of the person discharging managerial responsibilities/person closely associated | ||||
a) |
Name
|
Ms Rebecca Pynt | |||
2 |
Reason for the notification | ||||
a) |
Position/status
|
Spouse of Mr Christopher Nash, an Independent Non-executive Director of Chi-Med
| |||
b) |
Initial notification/Amendment
|
Initial notification | |||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) |
Name
|
Hutchison China MediTech Limited | |||
b) |
LEI
|
N/A | |||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) |
Description of the financial instrument, type of instrument Identification code
|
Ordinary Shares of US$1.00 each
DI ISIN: KYG4672N1016
ADS ISIN: US44842L1035
| |||
b) |
Nature of the transaction
|
Acquisition of 3,120 and 42 Ordinary Shares on August 4, 2016 at a price of GBP19.00 and GBP18.99 respectively
| |||
|
|
|
|
|
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
GBP19.00 |
3,120 |
|
|
|
|
GBP18.99 |
42 |
|
|
|
|
|
|
|
d) |
Aggregated information Aggregated volume Price
|
N/A | |||
e) |
Date of the transaction
|
2016-08-04 | |||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries |
|
|
Christian Hogg, CEO |
+852 2121 8200 |
|
|
|
|
International Media Enquiries |
|
|
Anthony Carlisle, |
+44 7973 611 888 (Mobile) |
anthony.carlisle@cdrconsultancy.co.uk |
Citigate Dewe Rogerson |
|
|
|
|
|
U.S. Based Media Enquiries |
|
|
Brad Miles, BMC Communications |
+1 (917) 570 7340 (Mobile) |
bmiles@bmccommunications.com |
|
|
|
Susan Duffy, BMC Communications |
+1 (917) 499 8887 (Mobile) |
sduffy@bmccommunications.com |
|
|
|
Investor Relations |
|
|
Brian Korb, The Trout Group |
+1 (917) 653 5122 (Mobile) |
bkorb@troutgroup.com |
|
|
|
David Dible, |
+44 7967 566 919 (Mobile) |
david.dible@citigatedr.co.uk |
Citigate Dewe Rogerson |
|
|
|
|
|
Panmure Gordon (UK) Limited |
|
|
Richard Gray / Andrew Potts |
+44 (20) 7886 2500 |
|